A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 26 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COVID-19 vaccine adjuvanted Novavax (Primary) ; Matrix-M1 Adjuvant
Indications COVID 2019 infections
Focus Adverse reactions
Acronyms hummingbird
Sponsors Novavax

Most Recent Events

16 Dec 2024 Planned End Date changed from 8 Sep 2025 to 25 Oct 2025.
22 Jan 2024 Status changed from recruiting to active, no longer recruiting.
11 Oct 2023 According to Novavax media release, data from this trial will be presented at the World Vaccine Congress Europe 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight